Join us this episode for a conversation with Norbert Weidner, MD, Professor and Chair of the Spinal Cord Injury Center at Heidelberg University Hospital. In this conversation we discuss results of the Neuroimmunophilin Nogo-A Antibody in Spinal Cord Injury (NISCI) trial, published in a paper titled "Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial" in the journal Lancet Neurology. In this paper Weidner and their NISCI team discuss the top-line findings from a large multi-center clinical trial where antibodies against Nogo-A were administered to the spinal space early after acquired SCI. We invite you to listen in as Dr. Weidner gives an insider perspective on the NISCI trial, and trust you will enjoy our conversation on intrathecal drug delivery in the acute phase of SCI.